CN221083599U - Adverse reaction evaluation ruler used after anti-tumor drug administration - Google Patents
Adverse reaction evaluation ruler used after anti-tumor drug administration Download PDFInfo
- Publication number
- CN221083599U CN221083599U CN202322084261.3U CN202322084261U CN221083599U CN 221083599 U CN221083599 U CN 221083599U CN 202322084261 U CN202322084261 U CN 202322084261U CN 221083599 U CN221083599 U CN 221083599U
- Authority
- CN
- China
- Prior art keywords
- symptom
- ruler
- scale
- adverse reaction
- mark
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010067484 Adverse reaction Diseases 0.000 title claims abstract description 31
- 230000006838 adverse reaction Effects 0.000 title claims abstract description 31
- 238000011156 evaluation Methods 0.000 title claims description 27
- 239000002246 antineoplastic agent Substances 0.000 title claims description 24
- 229940041181 antineoplastic drug Drugs 0.000 title claims description 23
- 238000001647 drug administration Methods 0.000 title description 8
- 208000024891 symptom Diseases 0.000 claims abstract description 61
- 208000010201 Exanthema Diseases 0.000 claims abstract description 30
- 201000005884 exanthem Diseases 0.000 claims abstract description 30
- 206010037844 rash Diseases 0.000 claims abstract description 30
- 208000003265 stomatitis Diseases 0.000 claims abstract description 24
- 231100000862 numbness Toxicity 0.000 claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 18
- 229940079593 drug Drugs 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 5
- 239000003550 marker Substances 0.000 claims description 4
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 208000004044 Hypesthesia Diseases 0.000 abstract description 20
- 208000034783 hypoesthesia Diseases 0.000 abstract description 20
- 230000000259 anti-tumor effect Effects 0.000 abstract description 5
- 230000001815 facial effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 4
- 210000002200 mouth mucosa Anatomy 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 206010031009 Oral pain Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010059516 Skin toxicity Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 231100000644 Toxic injury Toxicity 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000008921 facial expression Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 231100000438 skin toxicity Toxicity 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The utility model provides a scale for evaluating adverse reaction after anti-tumor medicine, which comprises a main scale and an auxiliary scale, wherein the front surface of the main scale is provided with a first observation port, one side of the first observation port is provided with a first symptom grading mark, the back surface of the main scale is provided with a second observation port, one side of the second observation port is provided with a second symptom grading mark, and one axial end of the main scale is provided with a slot; the front of the auxiliary ruler is provided with a plurality of first symptom example images with different grades, the back of the auxiliary ruler is provided with a plurality of second symptom example images with different grades, and the auxiliary ruler is inserted into the slot at one axial end of the main ruler. The first symptom example image and the second symptom example image on the auxiliary ruler are compared with actual symptoms of the patient, and the classification of oral mucositis, rash and numbness of hands and feet of the patient can be accurately judged by matching the first symptom classification mark and the second symptom classification mark which are arranged on the main ruler, so that doctors can be informed in time, and early intervention is given to the patient.
Description
Technical Field
The utility model relates to the technical field of medical instruments, in particular to an evaluation ruler for adverse reaction after anti-tumor medicines.
Background
In recent years, the clinical application of novel antitumor drugs is increasing, and the development of tumor immunotherapy is more and more advanced, and the development of tumor therapy is greatly improved. However, whether a molecular targeting drug or a traditional cytotoxicity drug, various adverse reactions such as heart insufficiency, liver injury, pulmonary fibrosis, skin adverse reaction and other toxic symptoms possibly caused when tumor cells are killed, the occurrence rate of the skin toxicity reaction of the anti-tumor drug is up to 40% -90%, and serious skin adverse reaction not only damages the life quality of patients, but also clinically reduces the therapeutic dosage of the drug, so that the therapeutic effect is weakened; and simultaneously, toxic injury is caused to patients, and serious patients are even life-threatening. The adverse reaction of the anti-tumor medicine on skin is manifested by oral mucositis, rash, numbness of hands and feet, etc.
The incidence rate of oral mucositis in the skin adverse reaction of the anti-tumor drug can reach more than 90%, which often causes oral pain, malnutrition, weight loss, life quality reduction of patients, and even reduces compliance and tolerance of anti-tumor treatment of the patients. The incidence rate of rash reaches 39.5% -84%. The main onset of the drug is 8-10 days after treatment, the peak is reached in 2 weeks, the drug gradually lightens and even disappears in 8 weeks after drug withdrawal, and the drug usually has periodic attacks and is mainly distributed on the rich sebaceous gland parts such as scalp, face, chest and back and the like. The moderate and severe rash is mishandled, which causes great pain to the body and mind of the patient. Numbness of hands and feet is a typical adverse reaction in the chemotherapy use process of oxaliplatin, paclitaxel and the like, the incidence rate is 85% -95%, and the numbness of hands and feet not only affects the physiological health of patients, but also seriously affects the daily life of the patients.
The correct evaluation of oral mucositis, rash and numbness of hands and feet is the first step of prevention and treatment, clinical nurses use word memory subjective evaluation or use paper evaluation tables to evaluate, on one hand, the differences are caused, on the other hand, the application is complicated and inconvenient, and a special tool capable of simultaneously evaluating oral mucositis, rash and numbness of hands and feet is clinically lacking. How to use a simple and easy-to-operate tool to help nurses evaluate oral mucositis, rash and numbness of hands and feet of patients for early intervention is an urgent need in the art.
Disclosure of utility model
Based on the above, the utility model aims to provide a post-drug adverse reaction evaluation ruler for anti-tumor drugs, which is convenient for nurses to evaluate oral mucositis, rash and numbness of hands and feet of patients so as to intervene early.
The utility model provides an evaluation ruler for adverse reaction after anti-tumor drug administration, which comprises:
The main scale is characterized in that a first observation port is formed in the front face of the main scale, a first symptom grading mark is arranged on one side of the first observation port, a second observation port is formed in the back face of the main scale, a second symptom grading mark is arranged on one side of the second observation port, and a slot is formed in one axial end of the main scale;
The auxiliary ruler is arranged on the front face of the auxiliary ruler, a plurality of first symptom example images with different grades are arranged on the back face of the auxiliary ruler, the auxiliary ruler is inserted into the slot at one axial end of the main ruler, and the auxiliary ruler can slide back and forth relative to the main ruler along the length direction of the slot, so that the first symptom example images with different grades are displayed at the first observation port, and the second symptom example images with different grades are displayed at the second observation port.
The evaluation ruler for adverse reaction after the anti-tumor drug is simple in structure, convenient to carry and convenient to operate, helps nurses evaluate oral mucositis, rash and numbness of hands and feet of patients in clinical work, specifically, the first symptom example image and the second symptom example image on the auxiliary ruler are compared with actual symptoms of the patients, and the classification of the oral mucositis, the rash and the numbness of hands and feet of the patients can be accurately judged by matching with the first symptom classification mark and the second symptom classification mark arranged on the main ruler, so that doctors can be informed timely, and early intervention is given to the patients.
Further, the scale for evaluating adverse reaction after anti-tumor drug administration, wherein the first symptom classification mark comprises an oral mucositis classification mark, and the first symptom example image comprises 4 different grades of oral mucositis symptom example images.
Further, the scale for evaluating adverse reaction after anti-tumor drug administration, wherein the second symptom classification mark comprises a rash classification mark and a hand and foot numbness classification mark, and the second symptom example image comprises 4 different grades of rash symptom example images.
Furthermore, the scale for evaluating adverse reaction after anti-tumor medicine is characterized in that the front of the main scale is also provided with a pain evaluation mark.
Further, the scale for evaluating adverse reaction after anti-tumor drug administration, wherein the pain evaluation mark comprises a digital grading mark and a face spectrogram positioned on the lower side of the digital grading mark.
Furthermore, the scale for evaluating adverse reaction after the anti-tumor drug is characterized in that one side or two sides of the edge of the back surface of the main scale are provided with scale marks.
Furthermore, the adverse reaction evaluation ruler after the anti-tumor drug is used for the anti-tumor drug, wherein transparent window plates are arranged on the first observation port and the second observation port.
Furthermore, the scale for evaluating adverse reaction after the anti-tumor drug is prepared from opaque materials.
Drawings
FIG. 1 is a schematic diagram of the front structure of the main scale of the present utility model;
FIG. 2 is a schematic view of the reverse side structure of the main scale of the present utility model;
FIG. 3 is a schematic view of the front structure of the auxiliary ruler of the utility model;
FIG. 4 is a schematic view of the reverse side construction of the auxiliary ruler of the present utility model;
description of main reference numerals:
1. A main scale; 2. a secondary ruler; 3. a first viewing port; 4. a second viewing port; 5. grading identification of oral mucositis; 6. an exemplary image of oral mucositis symptoms; 7. grading marks of rashes; 8. an example image of rash symptoms; 9. grading marks of numbness of hands and feet; 101. digital grading identification; 102. a face spectrogram; 11. graduation marks.
The utility model will be further described in the following detailed description in conjunction with the above-described figures.
Detailed Description
In order that the utility model may be readily understood, a more complete description of the utility model will be rendered by reference to the appended drawings. Several embodiments of the utility model are presented in the figures. This utility model may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete.
It will be understood that when an element is referred to as being "mounted" on another element, it can be directly on the other element or intervening elements may also be present. When an element is referred to as being "connected" to another element, it can be directly connected to the other element or intervening elements may also be present. The terms "vertical," "horizontal," "left," "right," and the like are used herein for illustrative purposes only.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this utility model belongs. The terminology used herein in the description of the utility model is for the purpose of describing particular embodiments only and is not intended to be limiting of the utility model. The term "and/or" as used herein includes any and all combinations of one or more of the associated listed items.
Referring to fig. 1 to 4, the evaluation ruler for adverse reaction after anti-tumor drug administration in the present utility model comprises a main ruler 1 and an auxiliary ruler 2, wherein a first observation port 3 is arranged on the front surface of the main ruler 1, a first symptom classification mark is arranged on one side of the first observation port 3, a second observation port 4 is arranged on the back surface of the main ruler 1, a second symptom classification mark is arranged on one side of the second observation port 4, and a slot is arranged at one axial end of the main ruler 1;
The front surface of the auxiliary ruler 2 is provided with a plurality of first symptom example images with different grades, the back surface of the auxiliary ruler 2 is provided with a plurality of second symptom example images with different grades, the auxiliary ruler 2 is inserted into the slot at one axial end of the main ruler 1, and the auxiliary ruler 2 can slide back and forth relative to the main ruler 1 along the length direction of the slot, so that the first symptom example images with different grades are displayed at the first observation port 3, and the second symptom example images with different grades are displayed at the second observation port 4.
Specifically, the first symptom classification identifier includes an oral mucositis classification identifier 5, and the first symptom example image includes an oral mucositis symptom example image 6 with 4 colors of class I, class II, class III and class IV, referring specifically to fig. 3.
Wherein, the content of the oral mucositis grading mark 5 is as follows table 1:
TABLE 1
Specifically, the second symptom classification mark comprises a rash classification mark 7 and a hand and foot numbness classification mark 9, specifically an international rash classification guide NCI-CTCAE version 5.0 and a Levi special sensory neurotoxicity classification standard, and the second symptom example image comprises a grade 1, a grade 2, a grade 3 and a grade 4 of 4 colored rash symptom example image 8, and particularly referring to fig. 4.
Wherein the contents of rash grading identification 7 are as follows in table 2:
TABLE 2
The contents of hand and foot numbness grading indicia 9 are shown in table 3 below:
TABLE 3 Table 3
In this embodiment, the main scale 1 is made of opaque material, so as to prevent the example images on the auxiliary scale 2 from interfering with the display of the oral mucositis classifying mark 5, the rash classifying mark 7 and the hand and foot numbness classifying mark 9 on the front and back sides of the main scale 1, so that the nurse can clearly see the contents of each classifying mark on the front and back sides of the main scale 1.
Referring specifically to fig. 1, the front surface of the main scale 1 is also provided with a pain assessment mark. The pain assessment mark comprises a digital grading mark 101 and a facial makeup map 102 positioned on the lower side of the digital grading mark 101. In practice, nurses can evaluate the pain class of patients based on the FRS-R facial makeup method and the NRS digital grading method. The specific evaluation mode is as follows: matching the facial expression of the patient with the facial spectrogram 102 to obtain corresponding facial makeup values, and bringing the facial makeup values into the digital grading mark 101 to obtain the pain condition of the patient. Specifically, in the digital hierarchy marker 101, 1 to 3 points do not affect sleep slightly, 4 to 6 points affect sleep moderately, and 7 to 10 points seriously affect sleep severely.
Further, referring to fig. 2, scale marks 11 are provided on both sides of the edge of the back surface of the main scale 1, so that the nurse can measure the rash of the patient.
Further, transparent window plates are arranged on the first observation port 3 and the second observation port 4 so as to seal the first observation port 3 and the second observation port 4.
The usage method of the adverse reaction evaluation ruler after the anti-tumor drug in the embodiment is as follows:
1. Evaluation of grading for oral mucositis: the auxiliary ruler 2 is pulled to continuously switch the oral mucosa symptom example image displayed at the first observation port 3 until an oral mucosa symptom example image matched with the current oral mucosa symptom of the patient is found, and then the grading condition of the oral mucositis of the patient is obtained by combining the content of the oral mucositis grading mark 5 on the front surface of the main ruler 1.
2. Evaluation of grading for rash, numbness of hands and feet: the auxiliary ruler 2 is pulled out, the rash symptom example image 8 displayed at the second observation port 4 is continuously switched until a rash symptom example image 8 matched with the current rash symptom of the patient is found, and then the grading conditions of the rash and the numbness of hands and feet of the patient are obtained by combining the content of the rash grading mark 7 and the content of the numbness of hands and feet grading mark 9 on the back side of the main ruler 1.
In summary, the evaluation ruler for adverse reaction after anti-tumor drug administration has a simple structure, is convenient to carry and operate, helps nurses evaluate oral mucositis, rash and numbness of hands and feet of patients in clinical work, specifically, the evaluation ruler can accurately judge the grading of oral mucositis, rash and numbness of hands and feet of patients by comparing the first symptom example image and the second symptom example image on the auxiliary ruler 2 with actual symptoms of the patients and matching with the first symptom grading mark and the second symptom grading mark arranged on the main ruler 1 so as to inform doctors in time and give early intervention to the patients.
In the description of the present specification, a description referring to terms "one embodiment," "some embodiments," "examples," "specific examples," or "some examples," etc., means that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the present invention. In this specification, schematic representations of the above terms do not necessarily refer to the same embodiments or examples. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples.
The foregoing examples illustrate only a few embodiments of the utility model and are described in detail herein without thereby limiting the scope of the utility model. It should be noted that it will be apparent to those skilled in the art that several variations and modifications can be made without departing from the spirit of the utility model, which are all within the scope of the utility model. Accordingly, the scope of protection of the present utility model is to be determined by the appended claims.
Claims (8)
1. A scale for post-drug adverse reaction assessment of an anti-neoplastic agent, comprising:
The main scale is characterized in that a first observation port is formed in the front face of the main scale, a first symptom grading mark is arranged on one side of the first observation port, a second observation port is formed in the back face of the main scale, a second symptom grading mark is arranged on one side of the second observation port, and a slot is formed in one axial end of the main scale;
The auxiliary ruler is arranged on the front face of the auxiliary ruler, a plurality of first symptom example images with different grades are arranged on the back face of the auxiliary ruler, the auxiliary ruler is inserted into the slot at one axial end of the main ruler, and the auxiliary ruler can slide back and forth relative to the main ruler along the length direction of the slot, so that the first symptom example images with different grades are displayed at the first observation port, and the second symptom example images with different grades are displayed at the second observation port.
2. The post-drug adverse reaction evaluation ruler for an antitumor drug according to claim 1, wherein the first symptom classification mark comprises an oral mucositis classification mark, and the first symptom example image comprises 4 different-grade oral mucositis symptom example images.
3. The post-drug adverse reaction evaluation ruler for antitumor drug according to claim 1, wherein the second symptom classification mark comprises a rash classification mark and a hand and foot numbness classification mark, and the second symptom example image comprises 4 different grades of rash symptom example images.
4. The scale for post-drug adverse reaction evaluation according to claim 1, wherein the front face of the main scale is further provided with a pain evaluation mark.
5. The post-drug adverse reaction evaluation ruler for an antitumor drug according to claim 4, wherein the pain evaluation marker comprises a digital grading marker and a face spectrogram located on the lower side of the digital grading marker.
6. The scale for evaluating adverse reaction after an antitumor drug according to claim 1, wherein one side or both sides of the edge of the back face of the main scale are provided with scale marks.
7. The post-drug adverse reaction evaluation ruler for antitumor drugs according to claim 1, wherein transparent window plates are provided on the first viewing port and the second viewing port.
8. The scale for post-drug adverse reaction evaluation according to claim 1, wherein the main scale is made of an opaque material.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202322084261.3U CN221083599U (en) | 2023-08-03 | 2023-08-03 | Adverse reaction evaluation ruler used after anti-tumor drug administration |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202322084261.3U CN221083599U (en) | 2023-08-03 | 2023-08-03 | Adverse reaction evaluation ruler used after anti-tumor drug administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN221083599U true CN221083599U (en) | 2024-06-07 |
Family
ID=91325825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202322084261.3U Active CN221083599U (en) | 2023-08-03 | 2023-08-03 | Adverse reaction evaluation ruler used after anti-tumor drug administration |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN221083599U (en) |
-
2023
- 2023-08-03 CN CN202322084261.3U patent/CN221083599U/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chung et al. | Locational relationship of the supraorbital notch or foramen and infraorbital and mental foramina in Koreans | |
| Garg et al. | Prevalence of three-rooted mandibular permanent first molars among the Indian population | |
| Sanabria et al. | Adverse effects of low-dose oral minoxidil for androgenetic alopecia in 435 patients | |
| Ravaglia et al. | Anthropometric characteristics of healthy Italian nonagenarians and centenarians | |
| CN221083599U (en) | Adverse reaction evaluation ruler used after anti-tumor drug administration | |
| Smajilagic et al. | Clinical and anatomy study of the human mental foramen | |
| López-Jornet et al. | A complication of lingual piercing: a case report | |
| MacKenzie‐Wood et al. | Melanoma: accuracy of clinical diagnosis | |
| İyidal et al. | Number and size of acquired melanocytic nevi and affecting risk factors in cases admitted to the dermatology clinic | |
| Loh et al. | Dyskeratosis congenita in two male cousins | |
| Roldan-Marin et al. | Solitary subungual neurofibroma: an uncommon finding and a review of the literature | |
| Andreadis et al. | Bilateral masseter and internal pterygoid muscle hypertrophy: a diagnostic challenge | |
| Crosby et al. | Dermatophytosis mimicking Kaposi’s sarcoma in human immunodeficiency virus disease | |
| Tansir et al. | Hydroxyurea-induced hyperpigmentation | |
| Majumder et al. | Significance of ethnic disparity in cephalometric analysis in Indian population | |
| CN206063134U (en) | A kind of medical pain Assessment slide calliper rule based on CPOT | |
| Murthy et al. | Herpetic whitlow | |
| Polisetty et al. | Neuraxial techniques in patients with lumbar tattoos: A national survey from New Zealand | |
| Huculak et al. | In vivo facial tissue depth study of African Nova Scotian children | |
| Chandran et al. | Oral Lesions in Neurofibromatosis type I: Report of a Case and Clinical Implications | |
| Fatahzadeh et al. | JOURNAL OF THE AMERICAN ACADEMY OF | |
| MARMELZAT | Secondary Hypertrophic Osteoarthropathy and Acanthosis Nigricans: Restudy of a Case Simulating Pachydermoperiostosis | |
| DE LIMA et al. | SJÖGREN SYNDROME IN AN ALLERGIC PATIENT UNDER COMBINED THERAPY | |
| Mukesh et al. | Determination of sexual dimorphism in Bikner city population in Rajasthan by odontometric study of permanent mandibular canine | |
| McKenna | Outcomes of Surgery in patients 90 years of age and older: Hosking MP, Warner MA, Lobdell CM, et al. JAMA 261: 1909, 1989 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| GR01 | Patent grant |